Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, Kang MJ, Heo WD, Shin EY, Schwartz MA, Kim EG (May 2013). "p21-Activated kinase 4 promotes prostate cancer progression through CREB". Oncogene. 32 (19): 2475–82. doi:10.1038/onc.2012.255. PMID22710715. S2CID24463782.
Ahmed T, Shea K, Masters JR, Jones GE, Wells CM (July 2008). "A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF". Cellular Signalling. 20 (7): 1320–8. doi:10.1016/j.cellsig.2008.02.021. PMID18424072.
Wong LE, Reynolds AB, Dissanayaka NT, Minden A (August 2010). "p120-catenin is a binding partner and substrate for Group B Pak kinases". Journal of Cellular Biochemistry. 110 (5): 1244–54. doi:10.1002/jcb.22639. PMID20564219. S2CID24567609.
Li Y, Wang D, Zhang H, Wang C, Dai W, Cheng Z, Wang G, Li F (October 2013). "P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer". Anatomical Record. 296 (10): 1561–7. doi:10.1002/ar.22754. PMID23873832. S2CID33508556.
Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, Cheng M, Zhao D, Li F (April 2012). "LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells". Cancer Letters. 317 (1): 24–32. doi:10.1016/j.canlet.2011.11.007. PMID22085492.
Ryu BJ, Kim S, Min B, Kim KY, Lee JS, Park WJ, Lee H, Kim SH, Park S (July 2014). "Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor". Cancer Letters. 349 (1): 45–50. doi:10.1016/j.canlet.2014.03.024. PMID24704155.
Park JK, Kim S, Han YJ, Kim SH, Kang NS, Lee H, Park S (June 2016). "The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor". Bioorganic & Medicinal Chemistry Letters. 26 (11): 2580–3. doi:10.1016/j.bmcl.2016.04.037. PMID27117431.
Song S, Li X, Guo J, Hao C, Feng Y, Guo B, Liu T, Zhang Q, Zhang Z, Li R, Wang J, Lin B, Li F, Zhao D, Cheng M (March 2015). "Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors". Organic & Biomolecular Chemistry. 13 (12): 3803–18. doi:10.1039/c5ob00037h. PMID25705811. S2CID205989042.
Wang Z, Zhang X, Yang Z, Du H, Wu Z, Gong J, Yan J, Zheng Q (October 2012). "MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells". Biochemical and Biophysical Research Communications. 427 (3): 444–9. doi:10.1016/j.bbrc.2012.06.123. PMID22766504.
Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY (January 2015). "MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4)". Molecular and Cellular Biochemistry. 399 (1–2): 77–86. doi:10.1007/s11010-014-2234-9. PMID25410752. S2CID17307710.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3 (1): 89. doi:10.1038/msb4100134. PMC1847948. PMID17353931.
Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, Kang MJ, Heo WD, Shin EY, Schwartz MA, Kim EG (May 2013). "p21-Activated kinase 4 promotes prostate cancer progression through CREB". Oncogene. 32 (19): 2475–82. doi:10.1038/onc.2012.255. PMID22710715. S2CID24463782.
Ahmed T, Shea K, Masters JR, Jones GE, Wells CM (July 2008). "A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF". Cellular Signalling. 20 (7): 1320–8. doi:10.1016/j.cellsig.2008.02.021. PMID18424072.
Wong LE, Reynolds AB, Dissanayaka NT, Minden A (August 2010). "p120-catenin is a binding partner and substrate for Group B Pak kinases". Journal of Cellular Biochemistry. 110 (5): 1244–54. doi:10.1002/jcb.22639. PMID20564219. S2CID24567609.
Li Y, Wang D, Zhang H, Wang C, Dai W, Cheng Z, Wang G, Li F (October 2013). "P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer". Anatomical Record. 296 (10): 1561–7. doi:10.1002/ar.22754. PMID23873832. S2CID33508556.
Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, Cheng M, Zhao D, Li F (April 2012). "LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells". Cancer Letters. 317 (1): 24–32. doi:10.1016/j.canlet.2011.11.007. PMID22085492.
Ryu BJ, Kim S, Min B, Kim KY, Lee JS, Park WJ, Lee H, Kim SH, Park S (July 2014). "Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor". Cancer Letters. 349 (1): 45–50. doi:10.1016/j.canlet.2014.03.024. PMID24704155.
Park JK, Kim S, Han YJ, Kim SH, Kang NS, Lee H, Park S (June 2016). "The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor". Bioorganic & Medicinal Chemistry Letters. 26 (11): 2580–3. doi:10.1016/j.bmcl.2016.04.037. PMID27117431.
Song S, Li X, Guo J, Hao C, Feng Y, Guo B, Liu T, Zhang Q, Zhang Z, Li R, Wang J, Lin B, Li F, Zhao D, Cheng M (March 2015). "Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors". Organic & Biomolecular Chemistry. 13 (12): 3803–18. doi:10.1039/c5ob00037h. PMID25705811. S2CID205989042.
Wang Z, Zhang X, Yang Z, Du H, Wu Z, Gong J, Yan J, Zheng Q (October 2012). "MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells". Biochemical and Biophysical Research Communications. 427 (3): 444–9. doi:10.1016/j.bbrc.2012.06.123. PMID22766504.
Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY (January 2015). "MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4)". Molecular and Cellular Biochemistry. 399 (1–2): 77–86. doi:10.1007/s11010-014-2234-9. PMID25410752. S2CID17307710.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3 (1): 89. doi:10.1038/msb4100134. PMC1847948. PMID17353931.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3 (1): 89. doi:10.1038/msb4100134. PMC1847948. PMID17353931.
Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, Kang MJ, Heo WD, Shin EY, Schwartz MA, Kim EG (May 2013). "p21-Activated kinase 4 promotes prostate cancer progression through CREB". Oncogene. 32 (19): 2475–82. doi:10.1038/onc.2012.255. PMID22710715. S2CID24463782.
Wong LE, Reynolds AB, Dissanayaka NT, Minden A (August 2010). "p120-catenin is a binding partner and substrate for Group B Pak kinases". Journal of Cellular Biochemistry. 110 (5): 1244–54. doi:10.1002/jcb.22639. PMID20564219. S2CID24567609.
Li Y, Wang D, Zhang H, Wang C, Dai W, Cheng Z, Wang G, Li F (October 2013). "P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer". Anatomical Record. 296 (10): 1561–7. doi:10.1002/ar.22754. PMID23873832. S2CID33508556.
Song S, Li X, Guo J, Hao C, Feng Y, Guo B, Liu T, Zhang Q, Zhang Z, Li R, Wang J, Lin B, Li F, Zhao D, Cheng M (March 2015). "Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors". Organic & Biomolecular Chemistry. 13 (12): 3803–18. doi:10.1039/c5ob00037h. PMID25705811. S2CID205989042.
Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY (January 2015). "MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4)". Molecular and Cellular Biochemistry. 399 (1–2): 77–86. doi:10.1007/s11010-014-2234-9. PMID25410752. S2CID17307710.